Abstract
A simple reversed-phase high-performance liquid chromatographic (HPLC) method has been developed for the simultaneous determination of the antiepileptic drugs (AEDs) zonisamide (ZNS), primidone (PRI), lamotrigine (LTG), phenobarbital (PB), phenytoin (PHT), oxcarbazepine (OXC), and carbamazepine (CBZ) and two of their active metabolites, monohydroxycarbamazepine (MHD) and carbamazepine 10,11-epoxide (CBZE) in human plasma. Plasma (100 μL) was pretreated by deproteinization with 300 μL methanol containing 20 μg mL−1 propranolol hydrochloride as internal standard. HPLC was performed on a C8 column (4.6 mm × 250 mm; particle size 5 μm) with methanol–acetonitrile–0.1% trifluoroacetic acid, 235:120:645 (v/v), as mobile phase at a flow rate of 1.5 mL min−1. ZNS, OXC, and CBZ were monitored by UV detection at 235 nm, and PRI, LTG, MHD, PB, PHT, and CBZE by UV detection at 215 nm. Relationships between response and concentration were linear over the concentration ranges 1–80 μg mL−1 for ZNS, 5–50 μg mL−1 for PRI, 1–25 μg mL−1 for LTG, 1–50 μg mL−1 for MHD, 5–100 μg mL−1 for PB, 1–10 μg mL−1 for CBZE, 0.5–25 μg mL−1 for OXC, 1–50 μg mL−1 for PHT, and 1–25 μg mL−1 for CBZ. Intra-day and inter-day reproducibility were adequate (coefficients of variation were ≤11.6%) and absolute recovery ranged from 95.2 ± 6.13 to 107.7 ± 7.76% for all the analytes; for the IS recovery was 98.69 ± 1.12%. The method was proved to be accurate, reproducible, convenient, and suitable for therapeutic monitoring of the nine analytes.
Similar content being viewed by others
References
Garnett WR, Anderson GD, Collins RJ (2005) In: Burton ME, Schentag JJ, Shaw LM, Evans WE (eds) Applied pharmacokinetics and pharmacodynamics—principles of therapeutic drug monitoring. Lippincott Williams & Wilkins, Philadelphia, pp 491–511
Rambeck B, Salke-Treumann A, May T, Boenigk HE (1990) Eur Neurol 30:79–83
Meir B, Svein IJ, Harvey JK, Renė H, Emilio P, Torbjörn T (2004) Epilepsy Res 61:1–48
Matsuo F (1999) Epilepsia 40:S30–S36
Perucca E (2001) Fund Clin Pharmacol 15:405–417
Holmes GL (2002) In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds) Antiepileptic drugs. Lippincott Williams & Wilkins, Philadelphia, pp 285–297
Baulac M (2002) In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds) Antiepileptic drugs. Lippincott Williams & Wilkins, Philadelphia, pp 514–521
Morris RG, Lee MYY, Cleanthous X, Black AB (2004) Ther Drug Monit 26:626–632
Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, Patsalos PN (2003) Ther Drug Monit 25:347–363
Sackellares JC, Donofrio PD, Wagner JG, Abou-Khalil B, Berent S, Hoyt KA (1985) Epilepsia 26:206–211
Kanarkowski R, Rybakowski J (1989) Psychiatr Pol 23(5–6):379–386
Gross AS (1998) Br J Clin Pharmacol 46:95–99
Eadie MJ (2001) Br J Clin Pharmacol 52:11S–20S
Touw DJ, Neef C, Thomson AH, Vinks AA (2005) Ther Drug Monit 27:10–18
Perucca E (2000) Clin Pharmacokinet 38:191–204
Sander JW (1993) Epilepsia 34:1007–1016
Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, Van Rijn CM (2000) Epilepsia 41:1364–1374
Emilio P (2006) Br J Clin Pharmacol 61:246–255
Kuelpmann WR, Oellerich M (1981) J Clin Biochem 19:249–258
Franceschi L, Furlanut M (2005) Pharmacol Res 51:297–302
Patil KM, Bodhankar SL (2005) J Pharm Biomed Anal 39:181–186
Levert H, Odou P, Robert H (2002) J Pharm Biomed Anal 28:517–525
Lensmeyer GL, Gidal BE, Wiebe DA (1997) Ther Drug Monit 19:292–300
Matar KM, Nicholls PJ, Tekle A, Bawazir SA, Al-Hassan MI (1999) Ther Drug Monit 21:559–566
Mandrioli M, Ghedini N, Albani F, Kenndler E, Raggi MA (2003) J Chromatogr B 783:253–263
Yoshida T, Imai K, Motohashi S, Hamano SI, Sato M (2006) J Pharm Biomed Anal 41:1386–1390
Juergens U (1987) J Chromatogr 385:233–240
Wad N (1984) J Chromatogr 305:127–133
Eto S, Noda H, Noda A (1994) J Chromatogr 658:385–390
Guidance for industry: bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, 2001
Snyder LR, Kirkland JJ, Glajch JL (1997) Practical HPLC method development. 2nd edn. Wiley, New York, pp 351–355
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ma, CL., Jiao, Z., Jie, Y. et al. Isocratic Reversed-Phase HPLC for Simultaneous Separation and Determination of Seven Antiepileptic Drugs and Two of their Active Metabolites in Human Plasma. Chroma 65, 267–275 (2007). https://doi.org/10.1365/s10337-006-0157-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1365/s10337-006-0157-7